Chemotherapeutic Agent

ApprovedSmall molecule

Day One Biopharmaceuticals

Chemotherapeutic Agent is one of 88 small molecule programs targeting Glioma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Breast CancerActive, not recruiting

GliomaPhase 3

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Breast CancerApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Chemotherapeutic Agent

Day One Biopharmaceuticals

Approved

1 2

Halaven

Eisai

Preclinical

38 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

MS Contin

Merck & Co.

Preclinical

2 5

Zolymbus

AbbVie

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

Spravato

WWim Janssens

Preclinical

2 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Not yet recruiting

Gastroesophageal Junction Adenocarcinoma

NCT07408609

Q2 2031

Phase 3Recruiting

Glioma

NCT05566795

Clinical

Trials by Indication[1]

Advanced NSCLC1 trial

ctDNA as a Biomarker for Treatment in Advanced NSCLC

Unknown status·FFuzhou General Hospital··NCT05486988·500 enrolled

Breast Cancer1 trial

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

Unknown status·FFudan University·Phase 4·NCT03799679·60 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·JJiangsu Cancer Institute & Hospital·Phase 2·NCT07408609·114 enrolled

Glioma1 trial

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Recruiting· Day One Biopharmaceuticals logo

Day One Biopharmaceuticals·Phase 3·NCT05566795·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Chemotherapeutic Agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chemotherapeutic Agent compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chemotherapeutic Agent. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Day One Biopharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Day One Biopharmaceuticals

Chemotherapeutic Agent

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Q2 2031

Trials by Indication[1]

Advanced NSCLC1 trial

Breast Cancer1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Glioma1 trial

References

Drug Info

Quick Facts

Related News